Did you miss our presentation at this year’s World EPA Congress in Amsterdam? Precision experts Richard Macaulay (VP, Global Pricing and Market Access) and David Carr (Director, Global Pricing and Market Access) presented “Gene Therapies Market Access: Lessons From The Past, Future Best Practice” which analyzes the access success of launched gene therapies and draws best-practice learnings for future gene therapies.

(more…)

In January, the Alliance for Regenerative Medicine (ARM) released its State of the Industry Briefing which highlighted a record-breaking year for 2021. $23.1B raised for the advanced medicines sector (a 16% increase from 2020), 2,261 ongoing regenerative medicine clinical trials globally, and the evolution from treating and curing rare monogenetic diseases to more prevalent indications. Could we see 10-20 approvals each year by 2025?

(more…)

Precision will be at this year’s Gene Therapy for Rare Disorders from March 7 – 10^th in Boston. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization of therapies for rare genetic disorders.

(more…)

To successfully increase speed-to-market for gene therapies, having a defined CQV (Commissioning, Qualification, and Validation) strategy is critical to project success. In this webinar co-sponsored by Precision ADVANCE and Project Farma, our panel of industry experts discuss tips for delivering efficient, reliable, GMP-compliant facilities and processes specific to gene therapy.

(more…)

We are in the midst of a therapeutic revolution. An H1 report released by Alliance for Regenerative Medicine (ARM) highlights a record-breaking year, with over 1,320 ongoing clinical trials worldwide and 1000+ therapeutic developers. As 2021 comes to an end, we are on track to expect the highest number of advanced therapy regulatory approvals, when compared to previous years.

(more…)